Articles
Duke Clinical & Transitional Science Institute’s Virtual Conversation – May 14,2024
Duke Clinical & Transitional Science Institute is seeking TTP Patients and Caregivers, to share their perspectives. Check out the flyer for more information.
In patients with suspected immune TTP, admission source impacts hospital length of stay and time to therapeutic plasma exchange impacts clinical outcomes
When immune thrombotic thrombocytopenic purpura (TTP) is suspected, outcomes are impacted by time to therapeutic plasma exchange (TPE). We evaluated the impact of time to TPE on outcomes in suspected TTP cases admitted through the Emergency Department (ED) vs. transferred from another facility (Transfer).
Paediatric patients with suspected immune thrombotic thrombocytopenic purpura also experience treatment delays
The Goal of this article is to Assess treatment delays in paediatric patients with TTP.
Patient-Reported Outcome Measures in Patients with Thrombotic Thrombocytopenic Purpura: A Systematic Review of the Literature
This goal of this article is to define the landscape of PROMs at present and their validity evidence in studies of patients with TTP.
Understanding TTP
What you need to know about thrombotic thrombocytopenic purpura (TTP). TTP is a serious condition that can be managed when treated quickly.
ADZYNMA Patient Support
cTTP is very rare and difficult to treat. ADZYNMA offers relief for a number of patients. If you need help obtaining medication for cTTP click the link below for patient assistance.
Cablivi Patient Support
Help your aTTP/iTTP* patients transition from hospital to home with CABLIVI.
PRESS RELEASE: Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
OSAKA, Japan, and CAMBRIDGE, Massachusetts, November 9, 2023 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.1,2
MAYARI Study
Living with iTTP? Worried about relapse? If you have an acute episode the MAYARI Study may interest you.
Clinical Trials
Have questions? We’ve got answers. Read more.
Patients and Families Overview
USTMA Patient Resources
Learn more about USTMA’s free patient resources.
Thrombocytopenia Copay Assistance Program
TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists are administered on a calendar-year basis. At the end of each calendar year, waitlist applications expire. Patients still seeking assistance must join waitlists for the subsequent calendar year.
PRESS RELEASE: Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
On Sunday, June 25, 2023, Takeda announced, interim data from our pivotal, Phase 3 clinical trial on TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP).
“You May Have This Disorder—And Not Even Know It”, Black Health Matters.com
Black Health Matters highlighted our Beloved Reeshemah Wynn.
Reeshemah Wynn went to the emergency room with what she thought was the flu, but she was later diagnosed with a rare blood disorder called aTTP.
“Health Following Recovery from Immune Thrombotic Thrombocytopenic Purpura: The Patient’s Perspective”, Blood Advances
Blood Adv 2023; 7 (9): 1813–1822. doi: https://doi.org/10.1182/bloodadvances.2022008342
Authors: Rachel A. Kelley, Marshall K. Cheney, Clare M. Martin, Spero Cataland, Lauren B. Quick, San Keller, Sara K. Vesely, Amanda J. Llaneza, Mohamad O. Khawandanah, Janna M. Journeycake, Julie A. Panepinto, Deirdra R. Terrell
“Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) – cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom”, Hematology
Hematology, 26:1, 465-472, DOI: https://doi.org/10.1080/16078454.2021.1945236
Authors: Steve Holmes, Lauren Podger, Catherine Bottomley, Ewelina Rzepa, Karen M. A. Bailey & Fleur Chandler (2021) Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) – cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom
Orpha.net, Portal for Rare Diseases
Learn more about Thrombotic thrombocytopenic purpura at Oprha.net, The portal for rare diseases and orphan drugs.
